Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells

Madeline Dennis,Alyssa Hurley,Nicholas Bray,Cameron Cordero,Jose Ilagan,Tony M. Mertz,Steven A. Roberts

DOI: https://doi.org/10.1371/journal.pgen.1011293

IF: 4.5

2024-05-29

PLoS Genetics

Abstract:APOBEC-induced mutations occur in 50% of sequenced human tumors, with APOBEC3A (A3A) being a major contributor to mutagenesis in breast cancer cells. The mechanisms that cause A3A activation and mutagenesis in breast cancers are still unknown. Here, we describe factors that influence basal A3A mRNA transcript levels in breast cancer cells. We found that basal A3A mRNA correlates with A3A protein levels and predicts the amount of APOBEC signature mutations in a panel of breast cancer cell lines, indicating that increased basal transcription may be one mechanism leading to breast cancer mutagenesis. We also show that alteration of ERBB2 expression can drive A3A mRNA levels, suggesting the enrichment of the APOBEC mutation signature in Her2-enriched breast cancer could in part result from elevated A3A transcription. Hierarchical clustering of transcripts in primary breast cancers determined that A3A mRNA was co-expressed with other genes functioning in viral restriction and interferon responses. However, reduction of STAT signaling via inhibitors or shRNA in breast cancer cell lines had only minor impact on A3A abundance. Analysis of single cell RNA-seq from primary tumors indicated that A3A mRNA was highest in infiltrating immune cells within the tumor, indicating that correlations of A3A with STAT signaling in primary tumors may be result from higher immune infiltrates and are not reflective of STAT signaling controlling A3A expression in breast cancer cells. Analysis of ATAC-seq data in multiple breast cancer cell lines identified two transcription factor sites in the APOBEC3A promoter region that could promote A3A transcription. We determined that Rel-A, and Bach1, which have binding sites in these peaks, elevated basal A3A expression. Our findings highlight a complex and variable set of transcriptional activators for A3A in breast cancer cells. The protein APOBEC3A (A3A) is a major cause of mutations in breast cancers by changing cytidines in single-stranded DNA to uridine. The amount of A3A transcript is elevated specifically in cancer cells containing A3A-induced mutations, suggesting that up-regulation of A3A transcription may be an underlying cause of cancer mutations. However, little is known about the factors that influence A3A transcript level in breast cancer. Here, we identify three different proteins that impact A3A transcription: Her2, Rel-A and Bach1. Her2 activation is a common oncogenic event in some breast cancer subtypes and likely alters transcription of a variety of genes, including APOBEC3A, through enhanced signaling pathways or cell stress signaling. Contrastingly, Rel-A and Bach1 are transcription factors that we provide evidence that likely impact A3A transcription by binding the A3A promoter. Additionally, we found that correlations between A3A expression and canonical A3A transcriptional regulators, STAT1 and STAT2, in primary tumors stems from immune cells infiltrating into the tumor instead of direct transcriptional regulation in breast cancer cells. Our results demonstrate that A3A transcriptional regulation is highly complex with multiple factors and inputs potentially leading to an increase in mutations.

genetics & heredity